# Phase I Study of SHR-2002 + SHR-1316 in Patients With Advanced Malignant Tumors

> **NCT05082545** · PHASE1 · COMPLETED · sponsor: **Atridia Pty Ltd.** · enrollment: 19 (actual)

## Conditions studied

- Advanced Malignant Tumors

## Interventions

- **DRUG:** SHR-2002 and SHR-1316

## Key facts

- **NCT ID:** NCT05082545
- **Lead sponsor:** Atridia Pty Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-23
- **Primary completion:** 2023-07-17
- **Final completion:** 2024-02-12
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2024-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05082545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05082545, "Phase I Study of SHR-2002 + SHR-1316 in Patients With Advanced Malignant Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05082545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*